Radiofrequency ablation of primary and metastatic malignant liver tumors.

F. Izzo, C. C. Barnett, S. A. Curley

Research output: Contribution to journalArticle

Abstract

The use of RF energy to treat unresectable liver tumors is unlikely to be curative for most patients; however, a subset of patients treated with RFA may achieve long-term disease-free survival. Longer follow-up of hepatic tumor patients treated with RFA is needed to determine long-term disease-free and overall survival rates. New metastatic tumors develop in many of these patients at an incidence rate comparable with those treated with surgical resection or cryoablation. Surgical resection remains the gold standard for treating metastatic and primary liver tumors; however, few patients are candidates for hepatic resection because of tumor size, number, location, or the presence of cirrhosis too severe to permit liver resection. Cryoablation of unresectable tumors has been an option for several years, but complications associated with the freezing of tissue can be problematic. RFA of unresectable liver tumors provides a relatively safe, highly effective method to achieve local disease control in some liver cancer patients who are not candidates for liver resection. Ongoing research and refinements in RF techniques and equipment may permit effective treatment of larger liver tumors and of malignant tumors at other body sites. Combining RFA of liver tumors with regional and/or systemic adjuvant treatments is being studied in attempts to reduce the incidence of development of new metastases and, thus, improve the overall survival rates of these patients.

Original languageEnglish
Pages (from-to)225-250
Number of pages26
JournalAdvances in Surgery
Volume35
Publication statusPublished - 2001

Fingerprint

Liver
Neoplasms
Cryosurgery
Disease-Free Survival
Survival Rate
Incidence
Liver Neoplasms
Freezing
Fibrosis
Neoplasm Metastasis
Equipment and Supplies
Therapeutics
Research

ASJC Scopus subject areas

  • Surgery

Cite this

Radiofrequency ablation of primary and metastatic malignant liver tumors. / Izzo, F.; Barnett, C. C.; Curley, S. A.

In: Advances in Surgery, Vol. 35, 2001, p. 225-250.

Research output: Contribution to journalArticle

Izzo, F. ; Barnett, C. C. ; Curley, S. A. / Radiofrequency ablation of primary and metastatic malignant liver tumors. In: Advances in Surgery. 2001 ; Vol. 35. pp. 225-250.
@article{57b33315b0ec4c06bdc5e9a76f58bade,
title = "Radiofrequency ablation of primary and metastatic malignant liver tumors.",
abstract = "The use of RF energy to treat unresectable liver tumors is unlikely to be curative for most patients; however, a subset of patients treated with RFA may achieve long-term disease-free survival. Longer follow-up of hepatic tumor patients treated with RFA is needed to determine long-term disease-free and overall survival rates. New metastatic tumors develop in many of these patients at an incidence rate comparable with those treated with surgical resection or cryoablation. Surgical resection remains the gold standard for treating metastatic and primary liver tumors; however, few patients are candidates for hepatic resection because of tumor size, number, location, or the presence of cirrhosis too severe to permit liver resection. Cryoablation of unresectable tumors has been an option for several years, but complications associated with the freezing of tissue can be problematic. RFA of unresectable liver tumors provides a relatively safe, highly effective method to achieve local disease control in some liver cancer patients who are not candidates for liver resection. Ongoing research and refinements in RF techniques and equipment may permit effective treatment of larger liver tumors and of malignant tumors at other body sites. Combining RFA of liver tumors with regional and/or systemic adjuvant treatments is being studied in attempts to reduce the incidence of development of new metastases and, thus, improve the overall survival rates of these patients.",
author = "F. Izzo and Barnett, {C. C.} and Curley, {S. A.}",
year = "2001",
language = "English",
volume = "35",
pages = "225--250",
journal = "Advances in Surgery",
issn = "0065-3411",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Radiofrequency ablation of primary and metastatic malignant liver tumors.

AU - Izzo, F.

AU - Barnett, C. C.

AU - Curley, S. A.

PY - 2001

Y1 - 2001

N2 - The use of RF energy to treat unresectable liver tumors is unlikely to be curative for most patients; however, a subset of patients treated with RFA may achieve long-term disease-free survival. Longer follow-up of hepatic tumor patients treated with RFA is needed to determine long-term disease-free and overall survival rates. New metastatic tumors develop in many of these patients at an incidence rate comparable with those treated with surgical resection or cryoablation. Surgical resection remains the gold standard for treating metastatic and primary liver tumors; however, few patients are candidates for hepatic resection because of tumor size, number, location, or the presence of cirrhosis too severe to permit liver resection. Cryoablation of unresectable tumors has been an option for several years, but complications associated with the freezing of tissue can be problematic. RFA of unresectable liver tumors provides a relatively safe, highly effective method to achieve local disease control in some liver cancer patients who are not candidates for liver resection. Ongoing research and refinements in RF techniques and equipment may permit effective treatment of larger liver tumors and of malignant tumors at other body sites. Combining RFA of liver tumors with regional and/or systemic adjuvant treatments is being studied in attempts to reduce the incidence of development of new metastases and, thus, improve the overall survival rates of these patients.

AB - The use of RF energy to treat unresectable liver tumors is unlikely to be curative for most patients; however, a subset of patients treated with RFA may achieve long-term disease-free survival. Longer follow-up of hepatic tumor patients treated with RFA is needed to determine long-term disease-free and overall survival rates. New metastatic tumors develop in many of these patients at an incidence rate comparable with those treated with surgical resection or cryoablation. Surgical resection remains the gold standard for treating metastatic and primary liver tumors; however, few patients are candidates for hepatic resection because of tumor size, number, location, or the presence of cirrhosis too severe to permit liver resection. Cryoablation of unresectable tumors has been an option for several years, but complications associated with the freezing of tissue can be problematic. RFA of unresectable liver tumors provides a relatively safe, highly effective method to achieve local disease control in some liver cancer patients who are not candidates for liver resection. Ongoing research and refinements in RF techniques and equipment may permit effective treatment of larger liver tumors and of malignant tumors at other body sites. Combining RFA of liver tumors with regional and/or systemic adjuvant treatments is being studied in attempts to reduce the incidence of development of new metastases and, thus, improve the overall survival rates of these patients.

UR - http://www.scopus.com/inward/record.url?scp=0035236749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035236749&partnerID=8YFLogxK

M3 - Article

C2 - 11579813

AN - SCOPUS:0035236749

VL - 35

SP - 225

EP - 250

JO - Advances in Surgery

JF - Advances in Surgery

SN - 0065-3411

ER -